曲妥珠单抗治疗Her-2阳性乳腺癌的最佳时长的研究进展

Research progress on optimal duration of trastuzumab in treating HER-2 positive breast cancer

曲妥珠单抗治疗人表皮生长因子受体2(Her-2)阳性乳腺癌的标准疗程是1年,过长的治疗时长会产生较多经济花费和不良反应。那么,缩短曲妥珠单抗治疗时长能否带来不差于1年的疗效,或者治疗的最佳时长是多久?现将针对这一问题进行阐述。

The standard course of trastuzumab for treating Her-2 positive breast cancer is one year,and the too long treatment produces more economic costs and adverse reactions.Then could shortening trastuzumab duration bring the curative effect no less than one year,or how long is the best treatment duration?This article elaborates this issue.